Idera Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Sep 08, 2010 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its drug discovery and development programs targeted to Toll-like Receptors and a general corporate update at the following conferences:
- The Rodman & Renshaw Annual Global Investment Conference on Wednesday, September 15 at 10:50 a.m. ET at the New York Palace Hotel, New York City
- The UBS Global Life Sciences Conference on Monday, September 20 at 7:30 a.m. ET at the Grand Hyatt New York Hotel in New York City
The live audio webcast presentations will be available in the Investor section of the company's website at http://www.iderapharma.com. Archived replays will also be available on the company's site for two weeks following the events. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. The company's proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Idera's pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit http://www.iderapharma.com.
SOURCE: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Teri Dahlman, 617-679-5519
tdahlman@iderapharma.com
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com